摘要
维利西呱是一种口服的可溶性鸟苷酸环化酶激活剂,用于治疗恶性慢性心力衰竭和左心室射血分数(LVEF)降低的患者。其通过一氧化氮–环鸟苷酸–蛋白激酶(NO-c GMP-PK)信号通路新机制,改善心肌收缩性,从而治疗心力衰竭。临床研究表明,维利西呱对慢性心力衰竭和LVEF降低的患者虽不能显著改善12周后NT-proBNP水平,但有降低NT-proBNP水平,改善LVEF和降低不良反应事件的趋势,同时该药物耐受性较好,具有很好的安全性。
vericiguat is an oral soluble guanylate cyclase activator, is used in treatment of patients with malignant chronic heart failure and decreased left ventricular ejection fraction（LVEF）. vericiguat can improve myocardial contractility and treat heart failure through the new mechanism of nitric oxide-cyclic guanosine monophosphate-protein kinase（NO-c GMP-PK） signaling pathway. Clinical studies have shown that although vericiguat can not significantly improve the NT-proBNP level after treatment for 12 weeks for patients with malignant chronic heart failure and decreased（LVEF）, there is a trend of decreasing NT-proBNP level, improving LVEF, and decreasing adverse events. At the same time vericiguat has better tolerance with good security
出处
《现代药物与临床》
CAS
2018年第1期193-196,共4页
Drugs & Clinic
